Thyroid carcinoma is the most frequent endocrine malignancy and accounts for around 3% of global cancer incidence. Different histologies and clinical scenarios make necessary a multidisciplinary approach that includes new diagnostic methods and surgical, radiopharmaceutical and systemic therapies. This guideline updates several aspects of management of thyroid cancer.

NENs are a heterogeneous family of tumors of challenging diagnosis and clinical management. Their incidence and prevalence continue to rise across all sites, stages and grades. Although improved diagnostic techniques have led to earlier detection and stage migration, the improved prognosis documented over time for advanced gastrointestinal and pancreatic neuroendocrine tumors also reflect improvements in therapy. The aim of this guideline is to update practical recommendations for the diagnosis and treatment of gastroenteropancreatic and lung NENs. Diagnostic procedures, histological classification and therapeutic options are briefly discussed, including surgery, liver-directed therapy, peptide receptor radionuclide therapy, and systemic hormonal, cytotoxic or targeted therapy, and treatment algorithms are provided.

3593 Background: Although surgical resection remains the treatment of choice for liver metastases from colorectal cancer, only a minority of pts are suitable for surgery. Preoperative chemotherapy allows secondary liver resection and subsequent long-term survival in some patients (pts)with unresectable CCR liver metastases Methods: The aim of this study was to evaluate the safety and efficacy of oxaliplatin 120 mg/m² day 1, CPT-11 150 mg/m² day 1 and 14, fluorouracil 2600 mg/m² days 1 and 14 and folinic acid 500 mg/m² days 1 and 14, every four weeks, in metastasic liver CCR patients either technically unresectable or with known poor prognostic factors for long term survival after surgery. Results: 39 pts (M/F: 30/9), median age 55 (28–77), median ECOG 1 (0–2) were included. Mean number of liver nodes and mean size were 6.7 and 6.1 cm, respectively. 22 pts (56.4%) were initially unresectable while 17 (43.6%) had poor prognostic factors including large tumor size (52.9%), multinodular (23.5%), ill-located (23.5) and/or bilobar metastases (35.3%).Overall response rate to induction chemotherapy was 64%, 3 pts (7.7%) progressed while on-therapy. 23 pts underwent secondary surgery, including hepatectomy (52.2%) and wedge resections (47.8%), with (n=10) or without radiofrequency. An R0 resection was achieved in 84 % of pts, with margins <1cm in 60.9% of them. Pathological complete response rate was 17.4%. After neoadyuvant chemotherapy, 11 out of 22 initially unresectable CCR pts underwent surgery with curative intent, including 9 of then with a R0 resection. After a median follow up of 15 months (4–40), median progression-free survival and overall survival have not been reached. Main grade 3–4 toxicity included anemia (7.7%), leucopenia (13.9%), neutropenia (30.8%), plaquetopenia (5.1%), vomiting (5.1%) and diarrhea (23%) 1 pt died due to postoperative complications. Conclusions: Induction therapy with this triplet regimen achieves a high resectability and pathological complete response rates. No significant financial relationships to disclose.

Pancreatic ductal adenocarcinoma, which represents 80% of pancreatic cancers, is mainly diagnosed when treatment with curative intent is not possible. Consequently, the overall five-year survival rate is extremely dismal—around 5% to 7%. In addition, pancreatic cancer is expected to become the second leading cause of cancer-related death by 2030. Therefore, advances in screening, prevention and treatment are urgently needed. Fortunately, a wide range of approaches could help shed light in this area. Beyond the use of cytological or histological samples focusing in diagnosis, a plethora of new approaches are currently being used for a deeper characterization of pancreatic ductal adenocarcinoma, including genetic, epigenetic, and/or proteo-transcriptomic techniques. Accordingly, the development of new analytical technologies using body fluids (blood, bile, urine, etc.) to analyze tumor derived molecules has become a priority in pancreatic ductal adenocarcinoma due to the hard accessibility to tumor samples. These types of technologies will lead us to improve the outcome of pancreatic ductal adenocarcinoma patients.